Cryotherapy has emerged as a primary treatment option for prostate cancer (CaP); however, incomplete ablation in the periphery of the cryogenic lesion can lead to recurrence. Accordingly, we investigated the use of a non-toxic adjunctive agent, vitamin D3 (VD3), with cryotherapy to sensitize CaP to low temperature-induced, non-ice rupture-related cell death. VD3 (calcitriol) has been identified as a possible adjunct in the treatment of cancer because of its antiproliferative and antitumorigenic properties. This study aimed to identify the cellular responses and molecular pathways activated when VD3 (calcitriol) is combined with cryotherapy in a murine CaP model. Single freeze-thaw events above À15 1C had little effect on cancer cell viability; however, pretreatment with calcitriol in conjunction with cryo significantly increased cell death. The À15 1C calcitriol combination increased cell death to 55% following a single freeze compared with negligible cell loss by freezing or calcitriol alone. Repeated cryo combination yielded 90% cell death compared with 65% in dual freeze-only cycles. Western blot analysis following calcitriol cryosensitization regimes confirmed the activation of apoptosis. Specifically, proapoptotic Bid and procaspase-3 were found to decrease at 1 h following combination treatment, indicating cleavage to the active forms. A parallel in vivo study confirmed the increased cell death when combining cryotherapy with calcitriol pretreatment. The development of an adjunctive therapy combining calcitriol and cryotherapy represents a potentially highly effective, less toxic, minimally invasive treatment option. These results suggest a role for calcitriol and cryo as a combinatorial treatment for CaP, with the potential for clinical translation.
Introduction
In 2010, an estimated 217 730 men will be diagnosed with prostate cancer (CaP) in the US. 1 Although the current treatment options available offer favorable cure rates, the development of new minimally invasive treatments are vital to improve patient quality of life. In 2008, the AUA issued a Best Practices Statement on cryosurgery for the treatment of CaP, indicating its emergence as a mainstream treatment option. 2 A report by Cohen et al. on 10-year patient outcome has shown cryoablation to be equivalent to that of other therapies used to treat CaP. 3 Advances in cryosurgery over the last 10-15 years have greatly increased treatment efficacy and decreased negative side effects. These advances include improvements in cryotechnology, the use of urethral warming devices to minimize urethral sloughing, computer-aided ultrasound to guide the ablation process, as well as thermocouples to monitor temperature. 2, 4 Cryotherapy, as with other thermal techniques, does not create a uniform treatment zone; rather, there is a gradient of temperature, from the center where the temperature is at its lowest, with elevated temperatures toward the periphery. 5 In the center, cells are typically destroyed because of physical ice rupture and after thaw necrosis. However, in the periphery, it has been shown that other forms of cell death are dominant, including apoptosis. [6] [7] [8] Local recurrence is thought to be a result of incomplete cell death in the periphery of the freeze zone. 9 Chemotherapeutic drugs have been used as combination treatments with cryotherapy to increase the efficacy of tumor cell death. [6] [7] [8] [9] Many of these drugs, such as taxotere and 5-fluorouracil, have been shown to sensitize CaP to freeze-induced apoptosis. [5] [6] [7] In vivo, however, chemotherapeutic drugs present toxic side effects as well as concern over drug resistance. Accordingly, the need for the identification of novel, non-toxic treatments for CaP is essential. For this reason, researchers continue to investigate possible adjuvants (cryosensitizers) that when combined with low temperature ablation can increase the level of cell death in the periphery of the cryolesion.
One compound that has shown promise as a cryosensitizer is vitamin D3 (VD3). 10, 11 Vitamin D circulates in the body bound to a vitamin D-binding protein and is converted to a biologically active form through two distinct hydroxylation reactions, forming first the precursor protein 25(OH)D 3 , followed by the active metabolite 1,25(OH) 2 D 3 (calcitriol). 12 Research has indicated that at least 10 organs in the body, including the prostate, have the ability to convert the precursor forms into the active metabolite, extending calcitriol production into the realm of paracrine signaling. 13 Calcitriol is a ligand for the vitamin D receptor, which is a member of the nuclear receptor superfamily and has a direct role in gene transcription through its binding to nuclear vitamin D response elements on the DNA. 14 Vitamin D response elements are present on many different genes, and therefore the effects that calcitriol elicits on a cell can be diverse.
VD3 is well known for its role in calcium and bone homeostasis; however, there is a wide range of emerging scientific literature documenting additional properties. 15 Research has suggested that there are both nuclear and cytosolic vitamin D receptors, and that each may have a different role in vitamin D signaling. 16 Calcitriol has also been implicated in the reduction of inflammation, which is critical to the initiation and progression of CaP, as tumor tissues can overexpress certain proinflammatory molecules, leading to cancer progression. 17 This is important in the early stages of CaP (that is, prostatic intraepithelial neoplasia), which represents cell transformation between normal epithelial cells and CaP cells. 18 More specifically, research has shown that prostate epithelial cells possess both the vitamin D receptor and the necessary enzymes to convert 25(OH)D 3 to 1,25(OH) 2 D 3 , and therefore can produce the biologically active metabolite of vitamin D. 19 However, other studies have demonstrated that as CaP progresses, these cells lose 1a-hydroxylase activity, the enzyme necessary for this conversion. 20 Therefore, CaP progression and development is associated with the loss of the prostatic epithelial cells to produce calcitriol, and as such calcitriol supplementation may help to inhibit the progression of the disease. Calcitriol has also been found to activate apoptosis in various cancers by increasing calcium levels as well as altering mitochondrial signaling. [21] [22] [23] [24] A recent parallel study by Kimura et al. described the use of VD3 as a cryosensitizer in an in vivo murine CaP model. 10 Their results demonstrated that intratumoral (i.t.) calcitriol injection into orthotopically grown tumors increased the area of necrosis and decreased the number of proliferating cells within the cryolesion after freezing. 10 Further, Baust et al. have also reported on the beneficial effects of VD3 in combination with freezing in an in vitro cell model. 11 These studies indicate that vitamin D and its downstream signaling molecules may represent a potential novel approach for CaP treatment. Although there is sufficient evidence to suggest that VD3 and related genes have a role in the tumor progression of many cancers, the molecular mechanisms by which this occurs are not well understood. Given the complex properties of VD3 coupled with reports on the use of VD3 as an adjunctive agent, 9, 11 we investigated the utilization and mechanisms of action of VD3 as a cryosensitizer in a short-term, direct exposure model in conjunction with a mild-freezing event, focusing analysis on both ablative capacity and the signaling mechanisms involved. This short-term direct exposure model was utilized in both in vitro and in vivo studies to further assess the potential of minimally invasive, non-systemic, short-term cryosensitization strategies, thereby reducing the potential of clinical complications, such as long-term dose delivery and toxicity. Data presented herein demonstrate that VD3 is a highly effective cryosensitizer yielding synergistic CaP cell death at À15 1C through the upregulation of the apoptotic cascade.
Materials and methods

Cell culture
The murine CaP cell line, RM-9, was obtained from Dr V Mouraviev (Duke University Medical School, Durham, NC, USA) and originally derived from the mouse prostate reconstitution model system (Baylor College of Medicine). 25 Cultures were maintained in Falcon T-75 flasks at 37 1C, 5% CO2 in Dulbecco's modified Eagle's medium (Caisson Labs, North Logan, UT, USA) with 10% fetal bovine serum (Caisson Labs), 1% penicillin/streptomycin (Mediatech, Manassas, VA, USA) and 10 mM HEPES (Calbiochem, Gibbstown, NJ, USA) with media exchange every 2 days. Experimental subcultures were plated into tissue culture ware at 5 Â 10 6 cm À2 2 days before use.
Freezing protocol
Costar 8-well strips (Corning, Lowell, MA, USA) with 100 ml medium per well or 60 mm Falcon dishes with 4 ml medium per dish were placed on a precooled block within a circulating temperature-controlled bath at a preset target temperature. Sample temperature was monitored with a type T thermocouple (Omega, Stamford, CT, USA), and ice nucleation was initiated by liquid nitrogen vapor (crystallized water vapor) when samples reached À2 1C ( ± 1 1C). Samples were held for 10 min at target temperatures (À10, À15 or À20 1C) and then allowed to thaw at room temperature (10 min) before recovery incubation at 37 1C or initiation of a repeat freeze-thaw cycle.
VD3 treatment
The 1,25a dihydroxyvitamin D3 (calcitriol, Calbiochem) was reconstituted in ethanol and diluted to final concentrations in Dulbecco's modified Eagle's medium immediately before application. Calcitriol dilutions (50, 75, 100 and 150 nM) were applied to samples 24 h before freezing and remained on samples during the first 24 h of recovery (37 1C).
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Cell viability
Cell viability was assessed using the metabolic activity assay alamarBlue (Invitrogen, Carlsbad, CA, USA), diluted 1:20 in Hanks balanced salt solution (Mediatech). Media was aspirated and replaced with 100 ml per well alamar-Blue for 1 h incubation at 37 1C, and subsequently analyzed with a Tecan SPECTRAFluorPlus plate reader (TECAN Austria GmbH, Grödig, Austria) at excitation l ¼ 530 nm and emission l ¼ 590 nm. Media was returned to samples and incubated under standard conditions. Assessment was repeated for 3 days of recovery.
Microscopy
Samples were treated with calcitriol for 24 h and then frozen to À15 1C as described. Phase-contrast images were taken 24 h after freeze using Zeiss Axiovert imaging software (Carl Zeiss Microimaging, Thornwood, NY, USA) using 10 Â magnification.
To confirm the role of apoptosis, parallel samples were treated as described; allowed to recover for 1, 8, and 24 h; then were labeled with tristain fluorescent probes, Hoechst (living cells, 0.06 mg ml -1 ), propidium iodide (necrotic cells, 0.007 mg ml -1 ) and YO-PRO-1 (apoptotic cells, 0.8 mM) (blue, red and green fluorescence, respectively) (Molecular Probes, Eugene, OR, USA). Probes were incubated for 20 min in the dark before imaging with Zeiss Axiovert software at 10 Â magnification.
Western blot
Total protein was isolated using radioimmunoprecipitation assay buffer with protease inhibitor cocktail and quantified using a bicinchoninic acid protein assay kit (Pierce, Thermo Scientific, Rockford, IL, USA). Equal amounts of protein (30-50 ug) were separated on 12% polyacrylamide gels for 50 min at 200 V and then transferred to polyvinylidene fluoride membranes using a semi-dry transfer system (Bio-Rad, Hercules, CA, USA) for 30 min at 15 V. Membranes were blocked with nonanimal protein buffer (G-Biosciences, Maryland Heights, MO, USA) for 1 h at room temperature. Membranes were exposed to primary antibody overnight at 4 1C in a humidity chamber; antibodies were diluted in a 1:2 solution of non-animal protein/Tris-buffered saline with 0.1% Tween-20. Primary antibodies included Bid (1:250), caspase-3 (1:500), caspase-9 (1:200), Akt (1:500) and Parp (1:500) (mu reactive, CST, Danvers, MA, USA). Membranes were then washed in Tris-buffered saline with 0.1% Tween-20 before 1 h room temperature secondary antibody hybridization in 1:2 non-animal protein/Tris-buffered saline with 0.1% Tween-20 with goat anti-rabbit HRP (1:10 000, Pierce) and StrepTactin-HRP (1:40 000, Bio-Rad) for molecular weight marker visualization. Membranes were then washed before detection using the LumiGLO/Peroxidase chemiluminescent detection kit (CST) on a FujiFilm LAS-3000 system (Fuji Film, Edison, NJ, USA). Molecular weight was confirmed by migration of the western C-HRP protein marker (Bio-Rad).
Data analysis
Relative fluorescent units were converted to percent survival as compared with 37 1C pretreatment controls. Viability percentages are expressed as percent ± s.e.m. Experiments were repeated a minimum of three times. One representative experiment was chosen and presented in Figures 1 and 2 ; each condition had an n of 7. Statistical analysis of significance was performed by single factor analysis of variance; statistically significant when Po0.05. Densitometry was performed on western blots using Fuji Film Multi Gauge software V2.3 (Fuji Film) and is described as percent of control with background values subtracted. Figure 1 Cell viability of RM-9 cells in response to low temperature exposure. Each freeze injury was imposed for a total time of 10 min, followed by 10 min of passive thawing at room temperature before recovery incubation at 37 1C. Repeat freeze exposure was conducted immediately following the 10 min passive thaw. Viability was assessed 1, 2 and 3 days after freeze. Percent survival based on prefreeze controls. Significant cell death did not occur following a single freeze event to À10 or À15 1C. Repeated 10 min, À15 1C freezes results in a loss of over half of the starting cell population. Exposure to cryotreatment at À20 1C significantly decreases cell survival (analysis of variance; *Po0.05).
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In vivo studies
Murine studies were performed at the Duke University under IACUC approval (Dr T Polascik). Briefly, hind leg tumors were created in mice by subcutaneous injection of RM-9 (2 Â 10 5 ) cells as previously described. 10 Animals were subjected to cryo (dual 15s per À40 1C, as measured by thermocouple monitoring at the core of the tumor) with 17-gauge argon cryoneedles (SeedNet, Galil, Plymouth Meeting, PA, USA), with or without calcitriol. Appropriate time was given between freeze cycles to allow for complete tissue thawing (B5 min). Calcitriol (4.0 mg kg À1 ) was administered via direct i.t. injection 18 h before cryo to mimic a short-term exposure ideal for in vivo treatment while also allowing sufficient time for cells to undergo a full cell cycle. Animals were sacrificed 24 h after treatment, and tumors were excised and stored at À80 1C. 10 Tissue samples were diced and homogenized both manually and via sonication (Fisher Scientific Sonic Dismembrator, Model 550, ThermoFisher Scientific, Waltham, MA, USA). Protein was then extracted with radioimmunoprecipitation assay buffer, and western blot analysis performed as described. Primary antibodies were hybridized overnight at 4 1C in 2 ml 1:2 non-animal protein/Tris-buffered saline with 0.1% Tween-20 and caspase-3 (1:500) or caspase-9 (1:200) (CST).
Results
Calcitriol pretreatment to low temperature exposure exerts a synergistic effect on cell viability
Analysis of sample viability indicated no effect on the RM-9 CaP cells when exposed to a range of calcitriol concentrations (25-150 nM), even in doses as high as 400 nM (data not shown). A freeze profile analysis of RM-9 cells in response to low temperature exposure indicated that following exposure to À10 or À15 1C viability was not significantly altered from time-matched 37 1C controls following 1 day of recovery (144±1.3 and 113 ± 1.0% versus 145 ± 1.5%, respectively) ( Figure 1) . A dual freeze-thaw cycle at À10 1C again yielded no significant reduction in cell number compared with controls (133±0.8%); however, following repeat exposure to À15 1C, a 55% loss of viability day 1 after treatment was observed, resulting in only 45±2.2% survival compared with prefreeze controls (Po0.05). Cryotreatment at À20 1C resulted in 11.5±0.6% survival 1 day after freeze for single applications and 1.5 ± 0.1% with no regrowth for repeat exposures, both of which were significantly lower than controls (Po0.05, Figure 1 ).
Following establishment of RM-9 response to freezing, cryosensitization studies using calcitriol before cryo were performed. Combinatorial treatment of calcitriol (50 nM) and a single freeze to À15 1C resulted in a 34 ± 3.1% decrease in viability as compared to time-matched freeze alone (Po0.01) ( Figure 2 ). Pretreatment with 75 nM calcitriol resulted in a decrease in viability to 59±2.1%, representing a 54 ± 2.1% decrease from the freeze alone (Po0.01). Pretreatment with 100 nM calcitriol followed by a single À15 1C exposure yielded 66 ± 4.7% cell death compared with time-matched À15 1C freeze alone (Po0.01). However, when calcitriol was increased to 150 nM, the observed level of cell death was reduced to 39 ± 3.5% compared with time-matched freeze alone samples. The 150 nM treatment was found to be less effective than the 75 and 100 nM treatments but similar to the 50 nM pretreatment condition (P ¼ 0.43).
As prostate cryosurgical procedures often utilize a dual freeze-thaw application to maximize ablation, we investigated the effect of a dual freeze calcitriol combination to determine whether cell death was enhanced. Repeat freeze exposure resulted in increased cell death compared with a single freeze for all concentrations of calcitriol examined (Figure 2 ). Cultures exposed to a dual À15 1C freeze alone yielded 33 ± 1.8% viability at 24 h after freeze compared with the 112±4.4% viability Figure 2 ). Phase microscopy evaluation of the samples exposed to calcitriol (50, 75, 100 and 150 nM) and a single À15 1C freeze confirmed the changes in cell morphology and level of cell death associated with cryosensitization using calcitriol and correlated with the metabolic activity viability assessment (Figure 3 ).
Fluorescent micrographs confirm apoptotic activation in combination treatments
To confirm the increased cell death determined by viability analysis in combination treatments, fluorescent microscopy was conducted to evaluate viable (Hoechst), apoptotic (Yo-PRO-1) and necrotic (PI) populations. These analyses corroborated the viability studies, with minimal necrosis/apoptosis (as seen by PI/Yo-PRO-1 staining) in non-frozen and VD3 controls. There was, however, a slight increase in necrotic staining cells in the VD3 control after 48 h of continual exposure (equivalent to 24 h experimental treatment and 24 h recovery). There was an increase in cell death in freeze alone over controls, which further increased following combination treatment as indicated by increased red/green staining. Analysis of combination samples revealed an increased level of apoptosis at 8 and 24 h of recovery, which was not seen in the freeze alone ( Figure 4 ).
Apoptotic signaling is increased in calcitriol and cryo combination treatment
To evaluate the mechanics of apoptotic cell death associated with calcitriol cryosensitization, temporal Calcitriol cryosensitization in prostate cancer KL Santucci et al western blot analysis was performed on after freeze samples ( Figure 5 ). Densitometric analysis of Bid, a proapoptotic protein that is cleaved when activated, revealed that cryo alone resulted in a small initial change from controls (10%) after 1 h of recovery, with a decrease to 36% of controls after 8 h of freezing. Following 24 h of recovery, Bid levels remained similar at 40%. With calcitriol treatment alone, Bid levels were 76, 58, and 70% of controls at 1, 8, and 24 h recovery, respectively. The largest decrease in Bid levels occurred in the combination treatments; at 1 h after freeze, samples pretreated with calcitriol exhibited a 53% reduction in protein compared with controls. After 8 h of recovery, Bid levels remained decreased at 42% of controls, with 24 h levels at 50% (Figure 5a ). Caspase-3, the 'executioner caspase', was also assessed to investigate involvement of the caspase cascade. The procaspase-3 precursor decreased slightly to 75% of controls 1 h after freeze, decreasing to 21% at 8 h. After 24 h, samples had recovered slightly to 37% of procaspase-3 control levels. Protein levels did not change significantly between the 1 and 8 h calcitriol alone controls, at 48 and 55%, respectively, although protein levels increased in the 24 h calcitriol control sample (87% of original 1 h control). In combination samples 1 h after freeze, 74% decrease in procaspase-3 over non-frozen controls was observed, indicating cleavage and caspase activation. At 8 h recovery, procaspase-3 levels remained low in the after freeze samples (21%), with the 24 h after freeze samples yielding higher levels (59%, Figure 5a ).
Along with pro-death signaling, the prosurvival signaling molecule Akt was investigated, given the surviving cell populations following freezing and cryosensitization seen in the initial viability studies. Assessment of Akt did not reveal significant variation in protein levels between controls, freeze alone, 50 nM VD3 or 150 nM VD3 (100, 118, 119 and 126%, respectively). When samples were exposed to a combination of 50 nM VD3 and a single À15 1C freeze, Akt levels increased twofold by 4 h recovery (211%, Figure 5b ). Levels of Akt were found to increase further to nearly threefold more than controls following combination treatment of freeze to À15 1C and 150 nM VD3 (266%), indicating phosphorylation, downstream signaling and subsequent upregulation. This observation correlated with the viability studies that showed treatment with high concentrations of calcitriol (150 nM) before freeze was associated with increased survival. Parp, a DNA repair protein, was also evaluated at 4 h after freeze in these samples. Analysis revealed the freeze alone condition to have 97% of control protein levels, 50 nM and 150 nM calcitriol resulted in 86% and 91% of controls, respectively, and combinations of freeze with 50 nM and freeze with 150 nM, 96 and 91%, respectively. As no significant changes in Parp levels were seen, this indicated that the À15 1C freeze with or without 50 or 150 nM of VD3 did not cause sufficient cellular damage to cleave Parp into an active form.
In vivo molecular analysis
The in vivo murine model also gave us insight into the molecular signaling pathways activated in response to calcitriol and cryotreatment. Procaspases-3 and -9 protein levels both decreased following calcitriol treatment as well as combination calcitriol and cryotreatment, but not in cryotreatment alone ( Figure 6 ). This indicated a higher level of apoptosis in the combination condition, supporting the activity of calcitriol as a cryosensitizing agent. The reduction of procaspase-9 protein levels following combination treatment may suggest a substantial mitochondrial-mediated pathway in calcitriol sensitization, which was also supported by the in vitro data with the observed Bid cleavage. It is possible that Bid initially translocates to the mitochondrial membrane and assists in the opening of mitochondrial permeability pores, allowing the release of cytochrome c from the mitochondria, formation of Apaf-1 and subsequent activation of caspase-9.
Discussion
Previous studies have identified VD3 as a potential cryosensitizer in human CaP cells in vitro. 11 In the current study, we further explored the role of calcitriol in the RM-9 system to evaluate the breadth of application potential across a variety of forms and stages of CaP. The RM-9 line is androgen responsive at low passages Figure 6 Protein levels from RM-9 cells following in vivo cryo, calcitriol and combinatorial treatment in a murine animal study. Table constructed based upon the western blot analysis described in Kimura et al. 2010 . Sections of tumor were excised from the right hind leg 24 h after treatment and tissue was homogenized; total protein was isolated and 50 ug per condition was separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride. Control (no treatment), Cryo 1 and 2 (two animals that each received cryoablation alone), Cal (calcitriol alone) and Combo 1 and Combo 2 (two animals that received the combination of calcitriol and cryo). Apoptotic signaling indicated by decreasing levels of procaspases-3 and -9 in combination and calcitriol treatments suggests cleavage and activation. Calcitriol cryosensitization in prostate cancer KL Santucci et al and non-responsive at higher passages, representing the critical stage of CaP progression to a more aggressive form. 26 Recently, it has been shown that late stage androgeninsensitive CaP is highly resistant to moderate freezing temperatures such as those associated with the periphery of a cryogenic lesion. 27 Given this, we focused our study on the periphery in an attempt to achieve complete cell death within the ice-ball margin, thereby preventing recurrence. We investigated the use of calcitriol as a cryosensitizer in an aggressive, rapidly dividing, late stage in vitro CaP model. We hypothesized that combining calcitriol with the moderate subfreezing temperatures experienced in the periphery of the cryogenic lesion would result in an increase in apoptotic cell death as compared with either cryotherapy or calcitriol treatment alone. Our results indicate that treatment with calcitriol before freezing sensitized CaP cells, thereby promoting an enhanced apoptotic and necrotic response following exposure to temperatures representative of those in the ice-ball margin (À15 1C). Moderate concentrations of calcitriol (75-100 nM) were found to be most effective, evident by the morphological, cellular and molecular markers of viability investigated herein.
With the confirmation of cryosensitization properties of calcitriol in the RM-9 model, investigation into the apoptotic signaling pathways activated during the freezing event were conducted. Immunoblotting revealed the reduction of procaspase-3, as well as the apoptotic precursor protein Bid, following combination treatment. These observed reductions were associated with protein activation and downstream apoptotic signal transduction. Interestingly, samples pretreated with calcitriol began to experience higher levels of apoptotic signaling at earlier time points than freeze-only samples, supporting the use of calcitriol in cryosensitization. The timing of apoptotic activation between 1 and 8 h was not unexpected given the short cell cycle time (B12 h) of RM-9 cells, thus allowing for a rapid response to the cellular stresses experienced during the freeze-thaw cycle.
In addition to the activation of apoptosis, the studies also demonstrated an increase in Akt levels following treatment with elevated calcitriol concentrations (150 nM). Akt upregulation seen at 4 h after freeze suggests prosurvival signaling through the PI3-kinase pathway may occur in response to high levels of VD3, affording cells protection from molecular-based freeze injury that correlated with the observed increased after freeze viability. These data suggest differential, dosedependent molecular pathway activation by calcitriol when utilized as a cryosensitizer at moderate (75-100 nM) and high (150 nM and above) concentrations. Many transcription factors can differ in their effects on a cell depending on both the concentration and duration of the signal received; it is possible that a high concentration of calcitriol in the cell exerts a different effect entirely by altering its interactions with binding sites on the DNA via nuclear transcriptional coregulators. 28 Our results indicate that cryosensitization with calcitriol concentrations of 75-100 nM in combination with À15 1C exposure resulted in increased cell death over freezing alone. However, reaching these effective therapeutic concentrations clinically poses difficulties. There have been several clinical trials on calcitriol in CaP studying various concentrations, methods of delivery and dosage schedules. Depending on the delivery method (oral, intravenous or subcutaneous), variances in peak serum calcitriol concentrations occurred. In an oral delivery study, the maximum serum concentration of 1,25(OH) 2 D 3 measured was 6 nM, 29 because of the fact that VD3 metabolism is tightly regulated in vivo. The i.t. injection, which was utilized in the Kimura et al. in vivo study, 10 may be a more effective method of delivery that would allow maximal calcitriol levels while limiting system toxicity. A previous study that investigated the use of intravenous versus i.t. drug injection efficacy of tumors in rats also supports the case for i.t. injection, with lower drug accumulation in vital organs and an overall improved antitumor treatment outcome. 30 Together, these results suggest that i.t. dosage should be further explored in calcitriol cryosensitization.
Serum concentrations were not measured in the Kimura et al. murine in vivo study, as the active 1,25(OH) 2 D 3 has a very short half-life of 15 h; however, the results indicate that a 4 mg kg À1 dosage was sufficient to induce cryosensitization. This study found significantly greater areas of necrotic tissue, as measured by hematoxylin and eosin staining, within tumors excised 24 h after freeze when pretreated for 18 h with calcitriol. These results also correlated with fluorescence immunohistochemistry, hypoxia and proliferation analyses, which suggest combination calcitriol and cryoablation therapy as superior to either alone. 10 For patients whose cancer remains localized and does not encompass the entire prostate, focal therapy is an area that may benefit from the use of cryosensitizers. Advancements in imaging are allowing for more accurate cryotherapy dosing, and by combining the use of sensitizing agents, treatments can become more effective with the same cryo dosage. This would allow reduction of the aggressive nature of current CaP cryoablation and subsequently reduce associated side effects. Overfreezing of the tumor often occurs because of the goal of complete ablation, but this can cause destruction of healthy surrounding tissue. 4 Owing to the close proximity of the prostate to the neurovascular bundle, overfreezing often leads to impotence and sexual dysfunction. 4 Additionally, the results of our study suggest the possibility that a single freeze-thaw cycle with calcitriol pretreatment may result in a similar level of cell death to the current dual freeze-thaw cycle standard. The switch to a single freeze event would reduce the risk of overfreezing, recurrence and procedural time, allowing enhanced CaP ablation in a shorter time. 5 Reducing these aforementioned effects would therefore give patients a better quality of life by preserving genitourinary function.
For over 15 years, researchers have been interested in the involvement of vitamin D and its downstream effects in cancer development and progression. However, the mechanism of action in vivo has not been elucidated, partly because of the fact that calcitriol can elicit varied results in different systems, making interpretation of treatment difficult. 31, 32 The cross talk between the downstream signaling effects of calcitriol and cryotherapy appears to more effectively activate apoptotic cascades than either alone. The exact role that calcitriol has in cryotherapy is still under investigation; however, the results obtained from the Kimura et al. in vivo murine Calcitriol cryosensitization in prostate cancer KL Santucci et al study correlate well with our in vitro findings, indicating that calcitriol sensitization may have benefits when applied clinically. 10 Issues of calcitriol concentration, dosage timing and dosage method still need to be addressed. Owing to the high risk of hypercalcemia as well as the reported challenges in reaching high serum levels of calcitriol in oral treatments, i.t. injection of calcitriol may provide a potential path for clinical utilization.
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